Girihlet Platform

About Girihlet

Founded in 2020 and based in San Francisco, Girihlet operates at the intersection of diagnostics, genetics, genomics, and AI-driven drug discovery. The company is building a multi-dimensional computational platform to discover new disease-monitoring and therapeutic strategies, with an initial focus on autoimmune diseases. A key near-term program is its ImmuneScanner diagnostic, which is being developed in collaboration with Mayo Clinic to monitor treatments for Ankylosing Spondylitis. Girihlet's approach positions it to leverage growing datasets in immunology to improve both clinical decision-making and pharmaceutical R&D.

Therapeutic Areas